790. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. 2. Johnson M, Campbell T, Clotet B et al. DUET-2: week-48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. In: Abstract 791. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. 3. Nelson M, Arasté h K, Clotet B et al. Durable efficacy of enfuvirtide over 48 weeks in heavily

more »

... HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005, 40: 404-12. 4. Harris M, Larsen G, Montaner J. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008; 22: 1224-6. 5. De Castro N, Braun J, Charreau I et al. Switch from enfuvirtide to raltegravir in highly treatment-experienced HIV-1-infected patients: a randomized open-label non-inferiority trial (EASIER -ANRS 138). In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009. Abstract 572. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. 6. Ruane P, Alas B, Fox S et al. A Phase IIIb pilot study substituting darunavir/ritonavir (DRV/r) and etravirine (ETR) for enfuvirtide (ENF) and current PI in a suppressive regimen. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2008. Abstract P068. www.hiv9.com. 7. Matt S, Kakuda T, Hanley W et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228-32. 8. Davis J, Scholler-Gyure M, Kakuda T et al. An open, randomised, two-period, crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. In: Abstracts of the Eleventh European AIDS Conference, Madrid, Spain, 2007. Abstract P4.3/02. www.eacs-conference2007.com. 9. Yazdanpanah YC, Fagard C, Descamps D et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: Results of the ANRS 139 TRIO trial. In: Abstracts of the Eleventh World AIDS Conference, Mexico City, Mexico, 2007. Abstract. THAB0406. www.aids2008.org. 10. Nozza S, Visco F, Soria A et al. Excellent short-term CD4 recovery with a PI-and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2008. Abstract P045. www.hiv9.com. 11. Imaz A, Villar del Saz S, Ribas M et al. Raltegravir, etravirine and ritonavir-boosted darunavir: a safe and successful rescue regimen for multi-drug resistant HIV-1 infection. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2008. Abstract P040. www.hiv9.com. 12. Vingerhoets J, Peeters M, Azijn H et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. In: Abstracts of the Seventeenth International HIV Drug Resistance Workshop, Sitges, Spain, 2008. Abstract 24. www. informedhorizons.com/resistance2008/.